Symbols

MRNA

Moderna·NASDAQ

--(--)

MRNA fundamentals

MRNA Q4 2025 Earnings

Moderna (MRNA) released its earnings on Feb 13, 2026: revenue was 678.00M (YoY -29.81%), beat estimates; EPS was -2.11 (YoY +27.49%), beat estimates.

Revenue / YoY

678.00M

-29.81%

EPS / YoY

-2.11

+27.49%

Report date

Feb 13, 2026

MRNA Earnings Call Summary for Q4,2025

Revenue resilience: 2025 revenue $1.9B, down 30% in operating expenses, with $8.1B cash despite FDA flu setback.
Pipeline progress: Intismeran Phase II melanoma shows 50% relapse reduction; norovirus Phase III enrolling; PA program nearing data.
2026 growth: Up to 10% revenue growth driven by international partnerships, mNEXSPIKE expansion, and flu/COVID combo vaccine filings.
Regulatory challenges: FDA flu vaccine refusal delays U.S. launch, but international filings advancing.

Earnings

EPS

Revenue

Revenue & Expenses

MRNA has released its 2025 Q4 earnings report, with revenue of 678.00M, reflecting a YoY change of -29.81%, and net profit of -826.00M, showing a YoY change of 26.25%. The Sankey diagram below clearly presents MRNA's revenue sources and cost distribution.

Key Indicators

Moderna (MRNA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Moderna (MRNA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Moderna (MRNA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Moderna (MRNA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown